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Abstract
High-frequency microsatellite unstable (MSI-H) colon tumors develop as a consequence of
mutations at repetitive sequences in target genes. TGFBR2 and ACVR2, encoding TGFb
superfamily receptors, and the proapoptotic gene BAX are frequent targets for frameshift mutation.
We analyzed the effect of these mutations on survival and histology in 2 separate cohorts. Forty-
eight MSI-H Dukes B2 colon tumors from a cohort of 172 patients had mutations in TGFBR2,
BAX and ACVR2 correlated with patient survival. Further, 54 population-based MSI-H colon
cancers of all stages from a cohort of 503 patients had mutations correlated with tumor stage,
grade and size. Of 44 amplifiable MSI-H Dukes B2 tumors, 70% harbored TGFBR2, 63% BAX
and only 4.5% ACVR2 mutations. While mutation alone did not influence survival, concomitant
mutation of TGFBR2 and BAX was associated with an improved prognosis in Dukes B2 patients (p
= 0.05). ACVR2 mutations were more frequent in the second, population-based cohort (stage II:
32.5%, p < 0.05). While no target gene mutation correlated with stage in this cohort, poor
histological grade and large tumor volume were associated with mutant ACVR2, but not TGFBR2
or BAX mutations, and likely accounts for the lower prevalence of ACVR2 mutations in the first,
well-differentiated Dukes B2 cohort. Because target gene mutations did not correlate with stage,
they likely occur early in the pathogenesis of MSI-H cancers. Mutations in TGFBR2 and BAX may
improve survival in MSI-H Dukes B2 patients, and mutations of ACVR2 may augment histological
changes consistent with poor tumor grade that is characteristic of MSI-H colon cancers, and
increase tumor size.
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Microsatellite unstable colon cancers are thought to develop genetically when key genes
containing coding microsatellites become frameshifted, inactivating the gene’s expressed
product. TGFBR2 encodes a receptor for TGFβ1, which seems to function as a growth
suppressor during colon tumor development, but later may enhance metastases. TGFBR2
contains an A10 microsatellite that is mutated in 60–90% of MSI-H colon cancers.1,2,3 BAX
encodes a proapoptotic protein important in triggering cell death and thus is a tumor
suppressor. Its G8 microsatellite is mutated in 40–60% of MSI-H colon cancers.4,5 ACVR2
encodes a specific receptor for activin, a TGFβ superfamily member. Its role in colon cancer
development is not fully clear, but it is likely to act as a tumor suppressor. ACVR2 contains 2
coding A8 microsatellites, of which the exon 10 microsatellite is frequently mutated in colon
cancer.6,7
Unlike chromosomal unstable colon cancers in which an accepted genetic pattern has been
well established for colon cancer progression that matches histological correlates, an
apparent pattern in MSI-H colon cancer is less clear. In MSI-H colon cancers, mutations in
TGFBR2 from tumors of stage III colon cancer patients is associated with an improved
survival.2 The onset of TGFBR2 mutations likely occur in high-grade dysplasia at the
interface between a benign adenoma and the development of carcioma.1 BAX may also
become mutated at this interface,5 which may affect responses to therapy or
chemoprevention.8 There are no data in this regard for ACVR2 in MSI-H colon cancers, nor
is there any data on histological correlates with ACVR2 mutations.
The importance of understanding the genetic changes in MSI-H colon cancers lies in the
difference seen in survival and response to therapy. For instance, several groups have shown
that patients with MSI-H colon cancer have an overall better survival than patients with non-
MSI-H tumors.9,10 Additionally, patients with MSI-H colon cancer do not respond to 5-FU
with increased survival like their non-MSI-H counterparts.11,12 Distinguishing features of
MSI-H tumors include: poorer grade, mucinous histology, a surrounding lymphocytic
infiltrate and location proximal to the splenic flexure of the colon.13
Here, we examined 2 cohorts to assess the influence of these target gene mutations in MSI-
H colon cancer. Specifically, we determined the survival outcome in node-negative MSI-H
colon cancers with TGFBR2, BAX and ACVR2 mutations. We also assessed mutational
status in a more advanced cohort and correlated target gene mutations with stage, and tumor
grade and size.
Material and methods
Patient selection and data collection
A total cohort of 172 patients with stage II (Astler-Collier-Dukes B2) colon cancers from the
U.S. (N = 84, which includes 70 from our previous publication14 plus an additional 14
patients from the University of California, San Diego Medical Center) and Switzerland (N =
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88) were previously collected between 1984 and 1989.14,15 A second cohort of 503 patients
with colon tumors were prospectively collected as part of the North Carolina Colon Cancer
Study (NCCCS), a population-based, case–control study comprising 503 patients.16 Both
studies were performed under IRB approval. The MSI status of most tumors in both cohorts
had been previously determined.7,14–16
All tumors were formalin-fixed and embedded in paraffin, then sliced into 5 μm sections. A
reference hematoxylin and eosin stain was performed on one cut, and on subsequent cuts,
the normal and tumor tissue were determined and marked for microdissection by a single
pathologist (KM), who was blinded to the results of the target gene analysis. Histological
grading was scored by the same experienced gastrointestinal pathologist using previously
described criteria for determining poor, moderate and well differentiation.17
DNA extraction
DNA was extracted from formalin-fixed, paraffin-embedded tissues of each patient’s colon
tumors and the surrounding noncancerous tissue as described previously.7,14 Unstained
tissues slices adjacent to the reference H&E stained slide were microdissected, according to
areas identified on the reference slide, by using a surgical scalpel blade, and areas of cancer
microdissected had >90% tumor cells. The dissected specimen was deparaffinized in a
microfuge tube with xylene, and the DNA was purified with ethanol and GeneReleaser (Bio
Ventures, Murfeesboro, TN), according to the manufacturer’s recommendations.
Subsequently, the samples were treated with 200 ug/ml of proteinase K (Sigma, St. Louis,
MO) and incubated at 55°C for 5 hr. Proteinase K was destroyed by heating the sample to
95°C for 15 min, and the samples were immediately iced and stored for polymerase chain
reaction (PCR) analysis.
Microsatellite analysis
MSI status was determined in all cancers using the National Cancer Institute-recommended
panel of 5 microsatellite markers (BAT25, BAT26, D5S346, D2S123 and D17S250)18 to
classify the tumor as MSI-high (associated with inactivation of DNA MMR) or
microsatellite stable (MSS), which is not associated with DNA MMR inactivation.
Primers were radiolabeled with 0.1 μCi (1 Ci = 37 GBq) of [γ-32P]dATP (DuPont/NEN).
PCR products were separated on 6% polyacrylamide gels containing 6 M urea, followed by
autoradiography. Mutations were determined by a change in the electrophoretic mobility of
the PCR products.
MSI-H tumors were defined as ≥2 of 5 markers with novel alleles compared to matched
nontumor DNA, whereas MSS tumors had 0 of 5 markers with novel alleles. Tumors with
1/5 markers positive were defined as MSI-low and were included with the MSS group as
non-MSI tumors. MSI-low tumors do not have MMR gene loss or inactivation.18
Amplification of the polyadenine tracts of target genes
Specific primers were designed to amplify the polyadenine tracts in exon 3 and exon 10 of
ACVR2 (exon 3, forward 5′-TCTGCTTATTTATAGGACTGATTGTG-3′ and reverse 5′-
Jung et al. Page 3






















CGCTGTGTGACTTCCATCTC-3′; exon 10, forward 5′-
GTTGCCATTTGAGGAGGAAA-3′ and reverse 5′-
CCTCTGAAAAGTGTTTTATTGGAA-3′) as well as TGFBR2 (forward 5′-
CTTTATTCTGGAAGATGCTG-3′ and reverse 5′-GAAGAAAGTCTCACCAGGC-3′) and
BAX (forward 5′-ATCCAGGATCGAGCAGGGCG-3′ and reverse 5′-
ACTCGCTCAGCTTCTTGGTG-3′). One primer from each set was radiolabeled with 32P,
and DNA was amplified in a thermocycler (MJ Research, Waltham, MA) in a reaction
containing 1 μM of each primer, 1× reaction buffer, 100 ng DNA template, 200 μM
deoxynucleotides, 1.5 μM magnesium chloride and 2.5 U Taq polymerase. PCR was carried
out over 29 cycles of 94, 54 and 72°C of 1 min each, preceded by a 3 min denaturing step at
94°C and followed by a 10 min extension step at 72°C. After PCR, the product bands were
analyzed on a 6% polyacrylamide gel and viewed with a phosphorimager (Molecular
Dynamics, Sunnyvale, CA) for band shifts comparing the tumor DNA to the paired normal
DNA. Each reaction and electrophoresis was repeated at least twice. In most of the cases,
direct DNA sequencing using an automated DNA Analyzer (Perkin Elmer) was used to
confirm mutations identified on the gels.
Statistical analysis
Statistical analyses were done by the UCSD Moores Comprehensive Cancer Center
Biostatistic Shared Resource utilizing SAS software. The following variables were assessed:
age, gender, location of the tumor within the colon, as well as stage, follow-up time and vital
status (alive or dead) if available. The location of the tumor was classified as right if the
tumor was at or proximal to the splenic flexure. Left-sided tumors were classified distal to
the splenic flexure. Disease stage was classified at surgery. Histological variables included
the grade of the tumor (well, moderate or poorly differentiated). Statistical analyses of these
descriptive values were as follows: for continuous variables, the t-test; for categorical
values, Fisher’s Exact Test; for pathological values, χ2 analysis.
Five-year survival analyses were done after classifying MSI-H tumors from patients and
whether their tumors had the absence or presence of target gene mutations. To examine
differences in survival rates, a Cox proportional hazard function was used for both
univariate and multivariate analyses. Univariate and multivariate survival distributions were
compared with the use of the logrank test. Multivariate analysis was only used to examine
the combined BAX and TGFBR2 mutations (controlled for tumor location) on survival.
Significance for all statistics, the likelihood of a difference between groups, was recorded if
the p value was 0.05 or less.
Results
Target gene mutations and survival in MSI-H Dukes B2 tumors
Table I depicts the clinical data from our Dukes B2 cohort, separated by MSI status. We
found no difference between gender (p = 0.88), follow-up (60.3 months for MSI-H vs. 58.9
months for MSS, p > 0.05) or age at diagnosis (p = 0.99) in patients with MSI-H versus
MSS tumors in this Dukes B2 cohort. Patients with MSI-H tumors had a lower overall
mortality than patients with MSS tumors, but this did not reach statistical significance (14%
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vs. 24%, p = 0.20). MSI-H Dukes B2 tumors were significantly more likely to be located
proximally in the colon (73% vs. 31%, p < 0.001). Overall, tumor grade was well to
moderately-differentiated in 87% of MSI-H tumors, not dissimilar to the MSS tumors within
the same cohort (93%) (p = 0.48) (Table I).
From the 172 Dukes B2 colon tumors analyzed, 48 (28%) were MSI-H, consistent with
previous reports of higher prevalences of MSI-H within earlier-staged tumors.2,19 Forty-four
tumors had DNA that amplified at all 3 target gene loci. Of those 44, 31 (70%) harbored
TGFBR2 mutations, 28 (63%) harbored BAX mutations, and only 2 (4.5%) had ACVR2
mutations. Fifty-two percent of all MSI-H tumors had mutations in both BAX and TGFBR2
and the 2 tumors with ACVR2 mutations also had mutations in TGFBR2 and BAX.
Contrary to what has been reported in stage III patients,2 we found no difference in survival
in our stage II patients with MSI-H tumors comparing those with and without TGFBR2
mutations (Table II). Similarly, there was no difference with BAX mutations and survival
(Table II). However, patients with both TGFBR2 and BAX mutations had a survival benefit
(p = 0.05), when compared to patients with 1 or no mutations present. When controlling for
tumor location utilizing multivariate analysis, TGFBR2 and BAX mutations together trended
as an independent predictive factor for survival (p = 0.09). Comparing the various
combinations of the TGFBR2 (mutated and wild type) and BAX (mutated and wild type)
gene status, we found no statistical differences between the combination of groups.
Target gene mutations occur independent of tumor stage
Because only 2 ACVR2 mutations were found in our Dukes B2 cohort, we analyzed a second
cohort from North Carolina, which we had previously examined for ACVR2 mutations, to
determine whether patient staging might explain the differences. This cohort, which lacked
survival data, was similar to our Dukes B2 cohort, in that there was no difference in gender
(although there was a trend toward more females in the MSI-H group, p = 0.06) or age at
presentation (p = 0.9), and MSI-H tumors were more likely to be located in the proximal
colon (p < 0.001) (Table III). However, this cohort is different from the Dukes B2 cohort, in
that MSI-H tumors had a significantly higher proportion of poorly-differentiated tumors
compared to MSS tumors. We found a higher number of ACVR2 mutations in stage II
patients in this cohort versus the Dukes B2 cohort (32.5% vs. 4.5%, p < 0.05). Overall, the
NCCCS cohort had 54/503 (11%) patients with MSI-H tumors, and 45/54 (83%) had
ACVR2 mutated.7 Forty-one patients with MSI-H tumors from this cohort with known stage
(2% A, 36% B, 57% C and 5% D) were analyzed as early (Dukes A + B) or advanced
(Dukes C + D) tumors with target gene mutational status. None of these assessed target
genes independently correlated with tumor stage, nor did the combined presence of ACVR2,
TGFBR2 and BAX mutations (Table IV).
ACVR2, but not TGFBR2 or BAX mutations, correlate with histologic grade and size of
tumor
Forty-seven of the MSI-H tumors from our NCCCS cohort had both grade and ACVR2
status available. Of 20 well- and moderately-differentiated tumors, 6 (30%) had wild-type
ACVR2, while only 1 of 27 (3%) poorly differentiated tumors was ACVR2 wild type (p <
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0.01) (Table V), whereas there was no significant difference in tumor grade with or without
TGFBR2 or BAX mutations (Table V).
Of the 54 MSI-H tumors with ACVR2 data, 28 tumors had 3D size data available: tumors
containing wild-type ACVR2 had a mean volume of 35 cm3 (median 13 cm3), and tumors
containing mutant ACVR2 had a mean volume of 99 cm3 (median 47 cm3) (p < 0.05) (Table
V). We found no statistical difference in size for tumors with and without TGFBR2 or BAX
mutations (Table V).
Discussion
Microsatellite unstable colon cancers develop and progress genetically as a consequence of
frameshift mutations in target genes. In this study, we found that: (i) although ACVR2
mutations tended to be less in stage II cancers, than in stage III and IV cancers, ACVR2
mutations were not significantly associated with stage (nor were TGFBR2 and BAX
mutations), (ii) ACVR2, but not TGFBR2 or BAX mutations, correlated with poorer tumor
differentiation, (iii) ACVR2, but not TGFBR2 or BAX mutations, correlated with larger
tumors, and (iv) patients with stage II colon cancer had improved survival with mutations in
both TGFBR2 and BAX, but not with either alone. There were not enough tumors with
ACVR2 mutations in the Dukes B2 cohort to determine any relationship between the
presence of ACVR2 mutations and patient survival. These findings indicate a role for target
genes in the progression of colon cancer, both at the histological stage and in regards to
patient survival.
In examining ACVR2 mutations in our 2 cohorts, we were surprised to find different
mutational prevalences among stage II patients. We found that the cohorts are different, in
that our Dukes B2 cohort is far better differentiated than our NCCCS cohort (87% vs. 42%
of MSI-H cancers, respectively) as designated by a single pathologist. Tumors with ACVR2
mutations are more likely to be poorly differentiated (Table V), which was not the case
when examining TGFBR2 and BAX mutations (Table V). We are confident in our detection
for frameshift mutations as we have previously shown that all frameshifts detected by gel
analysis revealed frameshift mutations upon sequencing, and that majority were biallelic and
lead to loss of protein expression.7 Contrary to that reported in cell lines, compound
heterozygotes do not appear to be a major concern in primary colon cancer tissue, at least for
detection of ACVR2 mutations. We also analyzed the exon 3 polyadenine tract of ACVR2,
and as previously reported,7 we did not find any mutation of this coding microsatellite in
any of the samples. Technical problems with identifying ACVR2 mutations in MSI-H
cancers can be excluded as both MSI-H-specific TGFBR2 and BAX mutations occurred
between cohorts, compared to the varied prevalence of ACVR2 mutations, and were
confirmed with repeated assays. Thus, tumor differentiation appears to be one predictor for
the presence of ACVR2 mutations in MSI-H tumors. Although additional differences might
contribute toward variation in the frequency of ACVR2 mutations between the cohorts, this
should have little impact on our results above, as both cohorts are analyzed separately for
different endpoints (survival in one cohort, and tumor size and differentiation in the other
cohort) with no direct comparison made between the cohorts. Last, we found a higher
percentage of MSI-H in our Dukes B2 cohort compared to that reported in the literature
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grouped for all stages (I–IV) of colon cancer. This is consistent with previous reports of
higher prevalences of MSI-H among earlier-staged colon tumors.2,19 We do acknowledge
that the earlier analysis may be limited by the few deaths observed in these Dukes B2
patients (Table II).
We found a significant difference in tumor size comparing MSI-H tumors with and without
AVCVR2, but not TGFBR2 or BAX mutations. Activin signaling is presumed to be growth
suppressive, and abrogation of signaling by a mutant ACVR2 (and subsequent loss of
ACVR2 expression) would augment growth. Since ACVR2 mutations segregated with larger
tumors, we believe that intact activin signaling may, in part, contribute to the physical size
of MSI-H tumors.
Although tumor size and differentiation has no influence on survival,20 the level of invasion
and stage remain the overall best predictors of prognosis.21 In comparing target gene
mutations and survival in our Dukes B2 cohort, we found no survival advantage for patients
with TGFBR2 or BAX mutations present. Because this cohort was overall well-differentiated
to moderately differentiated, the number of ACVR2 mutations was too low to make any
comparisons. When we combined TGFBR2 and BAX mutations, univariate analysis
predicted a survival advantage with this tumor genotype in MSI-H Dukes B2 patients.
TGFBR2 mutations are associated with an increased survival in stage III MSI-H patients.2
TGFβ signaling loss through TGFBR2 mutations might confer protection from the
“molecular switch” from growth suppression to one of metastasis enhancer,22 and improve
survival after the switch has occurred. In our Dukes B2 cohort, this suppressive to enhancer
switch may not be as marked as in stage III patients, as patients with Dukes B2 tumors are
discovered prior to the development of metastasis, and thus have improved survival on that
basis. That the combination of BAX with TGFBR2 mutations might confer a survival
advantage is more curious. Patients with BAX mutations within their MSI-H tumors were
found to have a diminished survival,4 although others have published opposite results.23 Our
finding of possible survival synergism between mutated BAX and TGFBR2 in patients with
MSI-H Dukes B2 colon cancer may suggest a possible interaction between defective
apoptotic pathways and defective TGFβ signaling that may prevent metastatic spread of the
tumor.
We found no correlation of target gene mutations and stage of MSI-H tumors. This suggests
that ACVR2, TGFBR2 and BAX mutations are likely to occur in high-grade dysplasia at the
interface of malignancy, which has been clearly described for TGFBR2 mutations.1
Likewise, BAX mutations in hereditary nonpolyposis colon cancer (HNPCC) tumors were
rare in adenomas, but common in cancers, suggesting that mutation occurs during malignant
transformation.5 We suggest here that ACVR2 mutations also are likely to occur earlier than
cancers in our cohort as well. Indeed, this idea is corroborated by a recent publication
demonstrating an equal ACVR2 mutation rate between HNPCC-associated MSI-H adenomas
(70.4%) and HNPCC-associated MSI-H carcinomas (71.8%).24
In summary, based on our findings examining MSI-H cancers from these 2 cohorts, we
suggest that target gene mutations occur prior to malignancy due to the target gene’s specific
genetic structure in the presence of dysfunctional DNA mismatch repair, but that the
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consequence of each target gene mutation may be observed at various times later in cancer
pathogenesis. Mutation of BAX may contribute to loss of programmed cell death to facilitate
malignant transformation, and later by unknown mechanisms further reduce metastases in
combination with TGFBR2 mutation in node-negative cancers. Mutation of TGFBR2 may
initially release the adenoma cells from TGFβ-induced growth suppression, but later protect
the host from metastases after some mechanism of functional switching of TGFβ into a
metastases enhancer. Mutations of ACVR2 may contribute to the release of adenoma cells
from growth suppression, but also augment histological changes consistent with poor tumor
grade that is characteristic of many MSI-H colon cancers, as well as increase local tumor
size. Target gene mutational status may influence grade, size and patient survival in MSI-H
colon cancers and this is the first report to analyze the clinical impact of ACVR2 mutations
in primary colon cancer specimens.
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TABLE II
TARGET GENE MUTATIONS AND SURVIVAL IN THE DUKES B2 COHORT WITH MSI-H1
Target gene Mutation status Alive (N) Dead (N) p-value
TGFBR2 (N = 45) Wild type   7 3 0.17
Mutated 31 4
BAX (N = 47) Wild type 14 4 0.15
Mutated 27 2
Both TGFBR2 and BAX (N = 44) None or either gene mutated 15 5 0.05
TGFBR2 mutated, BAX wild type   8 2
BAX mutated, TGFBR2 wild type   3 1
TGFBR2 wild Type, BAX wild type   4 2
TGFBR2 mutated, BAX mutated 23 1
1
Statistical significance was determined utilizing univariate analysis with the log rank test. TGFBR2 and BAX were compared as mutation positive
versus mutation absent. The combined TGFBR2 and BAX group was compared as both genes mutated versus all other combinations. Other
individual comparisons within the combined TGFBR2 and BAX group did not show statistical significance. p value is determined for mutated
versus nonmutated scenarios.
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TABLE III
CHARACTERISTICS OF NORTH CAROLINA COHORT1
Gender Average age (years) Location [proximal colon] Grade [well to moderate]
MSI-H [N = 54] M23 F31 63.7 32/54 (59) 20/47 (42)
MSS [N = 449] M251 F198 63.0 157/449 (35) 355/426 (83)
p-value 0.06 0.90 <0.001 <0.001
Values in parentheses indicate percentage values.
1
Of 503 colon cancers tested, 449 were non-MSI-H, and 54 (11%) were MSI-H. Survival data was not available for this cohort. Statistical
significance was determined utilizing the χ2 test.
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